Anavex Life Sciences Corp (AVXL)

[RedShoulder]

I continue to expect that initiation of a likely successful P3 Precision Medicine trial in AD will be the output from the P2b/3 results.

Investor2014, why do you continually post that you expect Anavex's Alzheimer Ph-2b/3 requiring another Ph-3 trial by the FDA , when Biogen/Eisal's drug LEQEMBI™ got FDA to award an AA approval on a Ph-2 that has less efficacy than Anavex's A2-73; and is not nearly as safe as A2-73 with adverse effects of brain swelling, brain bleeding, and resulting in several horrendous deaths? You negative assumption totally lacks logic.

"FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
JANUARY 6, 2023 • NEWS RELEASE
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™

https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembitm-lecanemab-irmb-under-accelerated-approval

Obviously if Biogen/Eisal can get approval on a Ph-2 trial, with serious adverse reactions, including the big one - potential death; and with much less efficacy than A2-73; then Anavex's A2-73 Blarcamesine is a lock for Accelerated Approval by the very same FDA.